Sage Journals: Discover world-class research

Abstract

Angiogenesis plays important roles in progression of hepatocellular carcinoma. The antiangiogenic mechanisms of vitexicarpine are not fully defined. Therefore, we conducted the following study to evaluate the antiangiogenic mechanism and antitumor activity of vitexicarpine in vivo model of hepatocellular carcinoma through modulation of vascular endothelial growth factor signaling pathway. Hepatocellular carcinoma was induced in Sprague Dawley rats by thioacetamide. Hepatocellular carcinoma was assessed by measuring serum alpha-fetoprotein and investigating liver sections stained with hematoxylin/eosin. Hepatocellular carcinoma rats were injected with vitexicarpine (150 mg/kg) for 2 weeks. Hepatic vascular endothelial growth factor was measured by enzyme-linked immunosorbent assay. Protein and expression of hepatic phospho-Ser473-AKT (p-AKT) and phospho-Tyr419-Src (p-Src) were determined. The apoptotic pathway was evaluated by assessment of protein expression of caspase-3. Vitexicarpine increased rats’ survival time and decreased serum alpha-fetoprotein as well as it ameliorated fibrosis and massive hepatic tissue breakdown. It attenuated hepatocellular carcinoma–induced protein and gene expression of vascular endothelial growth factor, p-AKT, p-Src, and caspase-3. In conclusion, this study suggests that vitexicarpine possesses both antiangiogenic and antitumor activities through inhibition of vascular endothelial growth factor, p-AKT/AKT, and p-Src with subsequent inhibition of apoptotic pathway.

Keywords

Hepatocellular carcinoma angiogenesis vascular endothelial growth factor p-AKT p-Src caspase-3

Introduction

Hepatocellular carcinoma (HCC) is a mutual, malignant tumor worldwide. Most cases of HCC develop in the background of liver cirrhosis.¹ Although sorafenib, vascular endothelial growth factor (VEGF) receptor and tyrosine kinase inhibitor, has been shown to extend the survival by nearly 3 months in patients with progressive HCC,^2,3 its therapeutic potential is restricted due to severe side effects and extraordinary high cost.^4,5 There are critical needs to explore possible alternative strategy that may effectively control HCC.

Angiogenesis is a key regulator of tumor growth and metastasis.⁶ Tumor angiogenesis may be controlled by angiogenic factors such as VEGF pathway through AKT and Src especially in HCC.^7,8 Various substances in Chinese medicinal herbs are assumed to be potent kinase inhibitors and demonstrated a preventive effect on cancer;⁹ among these herbs is vitexicarpine which is a flavonoid extracted from the fruits of Vitex rotundifolia.¹⁰ It has cytotoxic properties against human cancer cell lines¹¹ and inhibits the tumor necrosis factor-α (TNF-α)-induced vascular inflammation and T-lymphocyte proliferation.¹² It has been suggested that vitexicarpine could inhibit tumor growth and inflammation responses by negatively regulating angiogenesis. The antiangiogenic mechanism of vitexicarpine is not fully understood. Therefore, we conducted the following study to evaluate the vitexicarpine antiangiogenic activity and the extent of improvement of HCC in vivo model.

Materials and methods

Animals and their treatment outlines

The animal protocol was approved by the ethical committee of Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. All experiment procedures were conducted in compliance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (NIH publication no. 8023, revised 1978).

Thirty-one adult Sprague Dawley males weighing 180–200 g were kept for a week for acclimatization under standard conditions of temperature (25°C–27°C), with a regular 12-h dark–light cycle and allowed free access to standard rat food. Rats were classified into below groups.

Control group

Ten rats were allowed free access to standard rat food for 16 weeks and then were given normal saline containing dimethyl sulfoxide (DMSO; dilution 7:1; Sigma–Aldrich Chemicals Co., St Louise, MO, USA) by intra-peritoneal (i.p.) injection every other day in the 17th and 18th weeks and served as a control group.

HCC group

Twenty-one rats were given 200 mg/kg thioacetamide (Sigma–Aldrich Chemicals Co.) in normal saline by i.p. injection twice a week for 16 weeks.¹³

Vitexicarpine-HCC group

After week 16, eight rats of HCC group were chosen randomly and were given 150 mg/kg vitexicarpine in normal saline containing DMSO (7:1) by i.p. injection every other day for 2 weeks.¹⁴

Collection of rats’ samples

At the end of the study period, blood samples were collected by retro-orbital method and centrifuged at 4000 r/min for 5 min to collect sera, which were stored at −80°C. Rats were killed by decapitation, and then livers were removed, weighed, and divided into five parts. The first part was immediately immersed in liquid nitrogen and stored at −80°C for assessment of gene expression of total AKT and Src. The second part was homogenized in 10 mM phosphate-buffered saline (PBS), pH 7.4, for determination of malondialdehyde (MDA) and superoxide dismutase (SOD). The third part was fixed in 10% buffered formalin for morphological and immunohistochemical studies. The fourth part was homogenized in lysis puffer (Abcam, Cambridge, UK), for the determination of VEGF by rat enzyme-linked immunosorbent assay (ELISA). The last part was homogenized in radio immuno precipitation assay (RIPA) buffer for estimation of the protein expression of phospho-Ser473-AKT (p-AKT), phospho-Tyr419-Src (p-Src), and caspase-3.

Morphological analysis

Liver pieces fixed in 10% buffered formalin were embedded in paraffin. Five-micrometer-thick sections were cut and stained with Mayer’s hematoxylin and eosin (H/E) for examination of cell structure by light microscope. Liver specimens were anonymously coded and examined in a blinded manner. The morphological changes were photographed using a digital camera–aided computer system (Nikon Digital Camera, Japan).

Immunohistochemistry

Immunohistochemical analyses were performed on 5-µm-thick sections cut from a paraffin block of liver. Sections were deparaffinized by heating and rehydrated using xylene and descending concentrations of ethanol. Antigen retrieval was performed in citrate buffer solution (pH 6.0). Endogenous peroxidase was blocked with 0.1% Triton for 15 min. All non-specific binding sites were blocked using 1% bovine serum albumin for 1 h at 22°C. Sections were incubated overnight with polyclonal p-AKT and p-Src (1/500 in blocking buffer; Abcam) for 16 h at 4°C. Then sections were incubated with an Alexa Fluor® 488–conjugated goat anti-rabbit polyclonal (1/1000; Thermo Fisher Scientific, Rockford, USA). The chromogen used was 2% 3,3′-diaminobenzidine (DAB) in 50 mM Tris buffer (pH 7.6). Slides were counter stained with H and examined under microscope (Nikon Digital Camera).

Assessment of liver function

Serum alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT) activities as well as albumin concentration (Diamond Diagnostics, Giza, Egypt) were measured using standard colorimetric methodologies.

Assessment of oxidative stress

Oxidative stress was estimated in the liver homogenates through the following parameters:

MDA level was measured as described previously.¹⁵ In brief, after precipitation of proteins by trichloroacetic acid, thiobarbituric acid reacts with MDA to form thiobarbituric acid–reactive substance that is measured at 532 nm.

SOD activity was determined using phenazine methosulfate method,¹⁶ in which the ability of the enzyme to inhibit the phenazine methosulfate–mediated reaction of nitro blue tetrazolium dye is measured as an indication of the activity of SOD.

ELISA

The levels of biochemical parameters in liver homogenate and serum were measured by ELISA using a commercially available VEGF and alpha-fetoprotein (AFP), respectively (Abcam and USCN Life Science Inc., Houston, TX, USA, respectively) in accordance with the manufacturer’s instructions.

Quantitative, reverse transcription–polymerase chain reaction

Gene expression of total AKT, total Src, and caspase-3 in different rats’ hepatic tissues was determined using Maxima SYBR Green/Fluorescein qPCR Master Mix by Rotor-Gene Q (Qiagen, Hilden, Germany). Rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene and an internal reference control. Gene-specific polymerase chain reaction (PCR) primers were designed using Primer Express 3.0 (Applied Biosystems, Foster City, CA, USA) according to the nucleotide sequence obtained from the Gene Bank. Thermal cycling conditions included initial activation step at 95°C for 10 min followed by 30–40 cycles of 94°C for 15 s, 55°C or 58°C for 30 s, and 72°C for 1 min. The primer sequences, amplicon size, and annealing temperatures used for amplification are listed in Table 1. Melting curve analysis of the PCR products was performed to verify their specificity and identity. Rotor-Gene Q (Qiagen) collected data automatically and analyzed the value of threshold cycle (Ct). Rat total AKT, total Src, caspase-3, and GAPDH messenger RNA (mRNA) relative expression were determined using 2^−ΔΔCt method. PCR products were confirmed by running on 1.2% agarose gel electrophoresis.

Table 1.

The primer sets used for the detection of rat GAPDH, Src, and AKT.

Name	Sequence	Reference sequence	Amplicon size (bp)	Annealing temperature (°C)
GAPDH F	5′-CCATCAACGACCCCTTCATT-3′	NM_017008.3	193	58
GAPDH R	5′-CACGACATACTCAGCACCAGC-3′
Src F	5′-AGGTGGAGCACTACCGCATC-3′	NM_001003837.2	117	60
Src R	5′-AGAGTCCGTCGGCATCTGTG-3′
AKT F	5′-AATGACCGGGGAGTCCGAAT-3′	NM_001044712.1	110	63
AKT R	5′-ATGTGCTTCATCCTGCCCAC-3′

GAPDH: glyceraldehyde 3-phosphate dehydrogenase; F: forward; R: reverse.

All primers are rat primers.

Western blot analysis

Liver tissue homogenates were prepared in ice-cold RIPA buffer from various studied rat groups. Protein concentrations of supernatants were determined by Bio-Rad protein assay (Hercules, CA, USA). Protein denaturation was achieved by heating at 100°C for 5 min in the presence of 2× Laemmli sample buffer (4% sodium dodecyl sulfate (SDS), 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris–HCl). The samples were then subjected to SDS–polyacrylamide gel electrophoresis (PAGE).¹⁷ The protein profiles were electroblotted onto the nitrocellulose membranes (Millipore Inc., Billerica, MA, USA) at 4°C overnight. The antibody incubation procedures and the blocking buffer used were as per the antibody supplier’s instructions (Abcam). Image was acquired using darkroom development techniques for normal image scanning methods for colorimetric detection. Various targets were normalized using β-actin as the loading control.

Statistical analysis

The mean ± standard error (SE) was used for descriptive statistics of quantitative variables. For comparison of means between groups, one-way analysis of variance (ANOVA) was used. Once the differences exist among the means, post hoc Bonferroni correction test was calculated. Kaplan–Meier method was used for calculation of rats’ survival. Statistical computations were done using the computer software SPSS version 13 (Chicago, IL, USA), Microsoft Excel 2010, and statistical significance was predefined as p <0.05.

Results

Vitexicarpine reduced HCC-induced VEGF expression

HCC caused 2.6-fold increase in VEGF protein expression as compared with control group. Treatment with vitexicarpine partially reversed this effect in HCC (Figure 1).

Figure 1.

Vitexicarpine blocked vascular endothelial growth factor (VEGF) expression in vivo. Statistical analysis of VEGF concentration measured by ELISA showed a significant increase in HCC group (2.6-fold) compared with the control group. HCC rats treated with vitexicarpine blocked VEGF expression.

Antitumor activity of vitexicarpine

No death of rats was observed during treatment with vitexicarpine compared with more than 80% death in HCC group (Figure 2(a)). To confirm vitexicarpine’s antitumor activity, serum AFP level was measured in all animal groups (Figure 2(b)). Treatment with vitexicarpine significantly reduced HCC-induced elevation of AFP in HCC groups. There was also a notable increase in body mass and decrease in liver weight of vitexicarpine–HCC group (1.3- and 0.6-fold, respectively) as compared with HCC group.

Figure 2.

Antitumor activity of vitexicarpine. (a) Kaplan–Meier survival curves of rats. (b) Treatment with vitexicarpine significantly reduced HCC-induced elevation in serum AFP in HCC group. *Significant difference as compared with control group at p < 0.05. #Significant difference as compared with HCC group at p < 0.05.

Amelioration of vitexicarpine on HCC-induced disturbance in liver function

HCC elevated the activities of both ALT and GGT (14.1- and 6.6-fold, respectively) associated with decreased albumin concentration (37%) as compared with control group (Figure 3). Vitexicarpine treatment significantly improved the liver function in HCC.

Figure 3.

Effect of vitexicarpine on liver function. HCC rats treated with vitexicarpine showed a significant decrease in (a) serum alanine aminotransferase (ALT) and (b) gamma glutamyl transferase (GGT) as well as a significant increase in (c) serum albumin level as compared with HCC group.

Vitexicarpine ameliorates HCC-induced fibrosis

The improvement of the liver function by vitexicarpine was associated with hepatic morphological restoration. Histological examination of liver sections from HCC rats stained with H/E showed marked fibrosis and massive breakdown of hepatic tissues. However, sections from HCC rats treated with vitexicarpine showed nearly normal appearance of hepatic lobule (Figure 4).

Figure 4.

Hematoxylin and eosin–stained liver sections showed normal control, HCC, and vitexicarpine–HCC groups.

Vitexicarpine attenuated HCC-induced oxidative stress

The oxidative stress status has an important role in HCC development and progression. MDA and SOD measurements in liver homogenate samples showed a significant increase in MDA concentration (1.5-fold) and a significant decrease in SOD activity (27%) in HCC group as compared with the control group. Vitexicarpine treatment reversed these effects in HCC group (Figure 5).

Figure 5.

Hepatic measurements of superoxide dismutase (SOD, U/g) and malondialdehyde (MDA, nmol/g). A significant decrease in serum SOD activity and a significant increase in MDA in HCC group as compared with the control group. These effects were ameliorated by vitexicarpine.

Vitexicarpine blocked HCC-induced gene expression of total AKT

As illustrated in Figure 6, HCC group showed a significant increase in hepatic gene expression of total AKT (22.4-fold) compared with the control group. Treatment with vitexicarpine showed a strongly significant reduction in total AKT gene expression (0.08-fold) compared with HCC group, which reached a normal level.

Figure 6.

Relative gene expression of hepatic AKT mRNA and Src mRNA. HCC rats showed a significant increase in hepatic gene expression of total AKT and total Src as compared with the control group. Vitexicarpine normalized HCC-induced gene expression of total AKT.

Vitexicarpine reduced HCC-induced protein expression of p-AKT and p-Src

AKT and Src are activated by phosphorylation at Ser 473 and Tyr 419 sites, respectively. Accordingly, we studied the protein expression of phosphorylated AKT and Src by western blot using phospho-specific antibody against Ser 473 and Tyr 419, respectively. The expression p-AKT and p-Src was highly increased in HCC (5.9- and 8.8-fold, respectively) as compared with control group. While the treatment with vitexicarpine decreased the expression of p-AKT and p-Src (0.21- and 0.45-fold, respectively) as compared with HCC group (Figure 7). In addition, HCC showed a high increase in caspase-3 level (10-fold) as compared with the control group. However, treatment with vitexicarpine decreased caspase-3 level (0.41-fold) as compared with HCC group

Figure 7.

Western blot analysis showed protein expression of caspase-3, phospho-Tyr419-Src (p-Src), phospho-Ser473-AKT (p-AKT), and β-actin in different studied groups. Vitexicarpine partially decreased in p-AKT, p-Src, and caspase-3 as compared with HCC group.

Immunohistochemistry for p-AKT and p-Src

Rat liver sections stained with p-AKT and p-Src antibodies showed increased p-AKT and p-Src protein content in hepatocytes that was reduced by treatment with vitexicarpine (Figure 8).

Figure 8.

Immunohistochemical analysis of phospho-Ser 743-AKT (p-AKT) and phospho-Tyr419-Src (p-Src); both are partially decreased in vitexicarpine-treated rats as compared with HCC group.

Discussion

HCC is likely to produce angiogenic factors. VEGF is considered the strongest stimulator for angiogenesis, and it plays an important role in the course of carcinogenesis and metastasis.^18,19 It is a well-established fact that VEGF is significantly elevated in HCC,^20,21 as HCC is a highly vascular tumor, and tumor angiogenesis is critical for both its growth and metastasis.^5,22,23

AKT is thought to be involved in survival pathways by inhibiting apoptotic processes. It plays an important role in multiple cellular processes such as cell proliferation, apoptosis, oxidative stress, and cell migration.²⁴ We found significant elevation in the expression of p-AKT/AKT in HCC, which agreed with previous studies.^24–26 Many studies found a strong correlation between AKT activation and increased proliferation potential of HCC.²⁵

Src is closely associated with cancer progression and metastasis in humans. The HCC-induced activation of Src kinase correlates positively with cell proliferation, angiogenesis, motility, invasion, and migration.^27,28 We found a significant increase in Src activation in HCC. Lu et al.²⁹ found that the overexpression of Src could increase p-ERK, p-AKT, VEGF, and JNK1 protein levels. Therefore, p-Src/Src activates hepatocarcinogenesis. Furthermore, the up-regulation of Src and its downstream pathways induce oncogenic transformation. The angiogenic response of VEGF was suggested to proceed via G-protein-coupled protein kinase AKT, Ras-independent focal adhesion kinase–Src–PI3K–Raf–MEK protein networks, and tyrosine kinase–regulated heregulin-activated signal pathways.^30–35

Treatment with VEGF inhibitors markedly reduced the incidence of HCC in various studies.^36–38 The identification of inhibitors of VEGF and VEGF-related protein kinases is an attractive approach toward developing new therapies for metastatic tumors and chronic inflammatory diseases. Vitexicarpine, a herbal medicine, was reported to inhibit VEGF-induced angiogenesis in vitro.^39,40 Therefore, we examined vitexicarpine as a potentially novel anti-cancer agent in the treatment of HCC and tried to illustrate the pathways that may contribute to its angiogenic action. We found that treatment of HCC rats with vitexicarpine significantly reduced VEGF expression. This reduction in VEGF may have resulted by inhibiting the endothelial tube formation of cancer cells.²⁶ Furthermore, the significant decrease in gene expression of total AKT and phosphorylated AKT and Src by vitexicarpine treatment might be related to inhibition of VEGF. As AKT and Src play important role in angiogenesis, phosphorylation of them regulated VEGF signaling.^26,29,41

Oxidative stress is highly involved in the development and progression of HCC. We found significant elevated MDA levels associated with reduced activity of SOD in HCC, which was reversed by vitexicarpine. These results are similar to the results of Kadir et al.⁴² Antioxidant activity of vitexicarpine might be relevant to its free radical scavenging activity as well as the ability to release inducible nitric oxide synthase.⁴³ The reduction in the MDA levels is explained by the ability of vitexicarpine to avoid reactive oxygen species (ROS)-induced damage to membranes.^44,45 The antiangiogenic activity of vitexicarpine also may be explained by consuming intracellular SODs, as well as, the mitochondrial-associated manganese-dependent SOD and the cytoplasmic/nuclear copper/zinc-dependent SOD toward triggering a burst of NOS drove the expression of cell suicide regulator and produced selective killing of tumor cell leading to an antiangiogenic effect.¹⁰

Apoptosis plays a prominent part in the pathogenesis of HCC-induced liver injury.⁴⁶ Many previous studies suggest the role of caspase-3 in hepatocytes apoptosis.^47,48 The presence of specific ligands can propagate the apoptosis signal by direct cleavage of downstream effect or caspases such as caspase-3.⁴⁹ Indeed, we found a significant increase in caspase-3 expression in HCC group, which was blocked by vitexicarpine. Zhu et al.⁵⁰ suggest that vitexicarpine is a potent apoptosis-inducing agent in human NSCLC cells, which acts through both pathways involving mitochondria and death receptor with subsequent activation of caspases.

The anticarcinogenic effect of vitexicarpine was revealed by the improvement of the survival rate of HCC rats and by the reduction in serum AFP. In addition, vitexicarpine produced hepatoprotective effect against HCC-induced liver damage, which resulted in the improvement of cell structure and the reduction in the activities of both ALT and GGT in HCC rats’ treatment with vitexicarpine.

Conclusion

Vitexicarpine produced antiangiogenic and anti-apoptotic activities in vivo by blocking VEGF signaling through the inhibition of both p-AKT/AKT and p-Src/Src. Therefore, vitexicarpine might be a good candidate for additional evaluation as a novel therapeutic agent for HCC.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

The animal protocol was approved by the ethical committee of the Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. All experiment procedures were conducted in compliance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (NIH publication no. 8023, revised 1978).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Faculty of Pharmacy, Mansoura University, Egypt.

References

Schutte

Bornschein

Kahl

. Delayed diagnosis of HCC with chronic alcoholic liver disease. Liver Cancer 2012; 1(3–4): 257–266.

Heindryckx

Colle

Van Vlierberghe

. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009; 90(4): 367–386.

Kaseb

Hanbali

Cotant

. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009; 115: 4895–4906.

. Where are we in the chemoprevention of hepatocellular carcinoma? Hepatol 2010; 51: 734–736.

Darvesh

Aggarwal

Bishayee

. Curcumin and liver cancer: a review. Curr Pharmaceut Biotechnol 2012; 13: 218–228.

Hanahan

Folkman

. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.

Marme

. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J Urol 1996; 14: 166–174.

Chang

Wang

. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 2013; 13: 267.

Hou

Kumamoto

. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 2010; 13(5): 691–719.

10.

Wang

Zheng

Weng

. Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts. Life Sci 2004; 74(20): 2467–2478.

11.

Kobayakawa

Sato-Nishimori

Moriyasu

. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil). Cancer Lett 2004; 208(1): 59–64.

12.

Lee

Kim

. Vascular protective role of vitexicarpin isolated from Vitex rotundifolia in human umbilical vein endothelial cells. Inflammation 2011; 35: 584–593.

13.

Tayel

Abd

Galil

Ebrahim

. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur J Pharmacol 2014; 728: 151–160.

14.

Zhang

Lu Liu

Shiwen Zhao

. Vitexicarpin acts as a novel angiogenesis inhibitor and its target network. Evid Based Complement Alternat Med 2013; 2013: 278405.

15.

Draper

Hadley

. A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde. Xenobiotica 1990; 20: 901–907.

16.

DeChatelet

McCall

McPhail

. Superoxide dismutase activity in leukocytes. J Clin Invest 1974; 53: 1197–1201.

17.

Laemmli

. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227(5259): 680–685.

18.

Shi

Wang

. Expressions of vascular endothelial growth factor in cirrhotic tissues and their relations to proto-oncogene c-fos, c-myc. Hepatobiliary Pancreat Dis Int 2002; 1(3): 388–391.

19.

el-Houseini

Mohammed

Elshemey

. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005; 12: 248–253.

20.

Tan

Kim

El-Gazzaz

. Serum vascular endothelial growth factor level in patients with hepatocellular carcinoma undergoing liver transplantation: experience of a single Western center. Int J Organ Transplant Med 2012; 3(1): 42–51.

21.

Jeng

Sheen

Jeng

. PEDF effectively decreases VEGF to PEDF messenger RNA ratio of the inner edge of rat hepatocellular carcinoma induced by diethyl nitrosamine—an “in vivo” study. Hepatogastroenterology 2012; 59(117): 1484–1490.

22.

Chao

Chau

. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355–362.

23.

Kamel

Nessim

Abd-el-Hady

. Assessment of the clinical significance of serum vascular endothelial growth factor and matrix metalloproteinase-9 in patients with hepatocellular carcinoma. J Egypt Soc Parasitol 2005; 35(3): 875–890.

24.

Schattenberg

Nagel

Kim

. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012; 303(4): 498–506.

25.

Kaul

Saha

Saradhi

. Overexpression of hyaluronan-binding protein 1 (HABP1/p32/gC1qR) in HepG2 cells leads to increased hyaluronan synthesis and cell proliferation by up-regulation of cyclin D1 in AKT-dependent pathway. J Biol Chem 2012; 287(23): 19750–19764.

26.

Wang

Zheng

Zeng

. Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma. Int J Mol Med 2014; 33(2): 441–448.

27.

Sánchez-Bailón

Calcabrini

Gómez-Domínguez

. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal 2012; 24: 1276–1286.

28.

Ito

Kawakatsu

Takeda

. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J Hepatol 2001; 35: 68–73.

29.

Hsia

Yang

. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012; 33: 209–219.

30.

Montaner

Sodhi

Pece

. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 2001; 61: 2641–2648.

31.

Okajima

Thorgeirsson

. Opposite effects of ERK and P38 MAP kinase pathways on VEGF expression in rat liver epithelial cell lines. Proc Am Soc Cancer Res 2000; 41: 791.

32.

Solomon

O’Rourke

. Epidermal growth factor receptor (EGFR) regulates vascular endothelial growth factor (VEGF) transcriptional activation in human glioblastoma cell by hypoxia independent pathway involving Ras and P (I) 3 kinase. Proc Am Soc Cancer Res 2000; 41: 790.

33.

Sdohi

Montauer

Patel

. The Kaposi’s sarcoma associated Herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through nitrogen-activated protein kinase and P38 pathways acting on hypoxia-inducible factor 1α. Cancer Res 2000; 60: 4873–4880.

34.

Tsuzuki

Fukumura

Oosthuyse

. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α-hypoxia response element-VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000; 60: 6248–6252.

35.

Tadlock

Patel

. Involvement of P38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatol 2001; 33: 41–51.

36.

Hato

Zhu

Duda

. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016; 3: 299–313.

37.

Zhou

Amin

Fowler

. Complete response to erlotinib and bevacizumab in a patient with biphenotypic (hepatobiliary) primary liver carcinoma. J Natl Compr Canc Netw 2015; 13(12): 1468–1473.

38.

Weng

Song

. Blockade of the CXCR6 signaling inhibits growth and invasion of hepatocellular carcinoma cells through inhibition of the VEGF expression. Int J Immunopathol Pharmacol 2014; 27(4): 553–561.

39.

Choi

Eun

Kim

. Vitexin, an HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Mol Cells 2006; 22(3): 291–299.

40.

Liou

BinLen

JuWu

. Casticin inhibits COX-2 and iNOS expression via suppression of NF-κB and MAPK signaling in lipopolysaccharide-stimulated mouse macrophages. J Ethnopharmacol 2014; 158: 310–316.

41.

Adya

Tan

Punn

. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78(2): 356–365.

42.

Kadir

Kassim

Abdulla

. Hepatoprotective role of ethanolic extract of Vitex negundo in thioacetamide-induced liver fibrosis in male rats. Evid Based Complement Alternat Med 2013; 2013: 739850.

43.

Kadir

Kassim

Abdulla

. Hepatoprotective role of ethanolic extract of vitex negundo in thioacetamide-induced liver fibrosis in male rats. Evid Based Complement Alternat Med 2013; 2013: 739850. DOI: 10.1155/2013/739850.

44.

Kikuchi

Yuan

Yuhara

. Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytocidal effects against the human promyelocytic cell line HL-60. Int J Oncol 2013; 43: 2046–2056.

45.

Moreno

Campos-Shimada

da Costa

. Vitex agnus-castus L. (Verbenaceae) improves the liver lipid metabolism and redox state of ovariectomized rats. Evid Based Complement Alternat Med 2015; 2015: 212378.

46.

Persad

Liu

. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol 2004; 17: 861–867.

47.

Liang

Zhou

Zhang

. A novel chenodeoxycholic acid-verticinone ester induces apoptosis and cell cycle arrest in HepG2 cells. Steroids 2012; 77(13): 1381–1390.

48.

Zhang

Ding

. The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells. Food Chem Toxicol 2014; 63: 38–47.

49.

Schattenberg

Nagel

Kim

. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012; 303: 498–506.

50.

Zhu

Yang

. Effects of sesquiterpene, flavonoid and coumarin types of compounds from Artemisia annua L. on production of mediators of angiogenesis. Pharmacol Rep 2013; 65(2): 410–420.

Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway

Abstract

Keywords

Introduction

Materials and methods

Animals and their treatment outlines

Control group

HCC group

Vitexicarpine-HCC group

Collection of rats’ samples

Morphological analysis

Immunohistochemistry

Assessment of liver function

Assessment of oxidative stress

ELISA

Quantitative, reverse transcription–polymerase chain reaction

Western blot analysis

Statistical analysis

Results

Vitexicarpine reduced HCC-induced VEGF expression

Antitumor activity of vitexicarpine

Amelioration of vitexicarpine on HCC-induced disturbance in liver function

Vitexicarpine ameliorates HCC-induced fibrosis

Vitexicarpine attenuated HCC-induced oxidative stress

Vitexicarpine blocked HCC-induced gene expression of total AKT

Vitexicarpine reduced HCC-induced protein expression of p-AKT and p-Src

Immunohistochemistry for p-AKT and p-Src

Discussion

Conclusion

Footnotes

Declaration of conflicting interests

Ethical approval

Funding

References